Efficacy of Inotuzumab Ozogamicin When Used as Salvage/Bridging Therapy Prior to CD19-Directed CAR-T Therapy in Relapsed/Refractory B-ALL: A Single-Center Experience (SOHO 2026) - Sep 1, 2026 - Abstract #ALL-772; Location: LEVEL 3, HALL B3; "We evaluated the safety and efficacy of InO prior to talicabtagene autoleucel (Tali-cel)...Following fludarabine-cyclophosphamide conditioning, patients received either a single Tali-cel infusion of 5 × 106 or more CAR T cells/kg...Specifically, 15% received single-agent InO, while the remainder received combination therapy, most commonly mini-hyper-CVD (54.3%); ponatinib was the most common TKI used... InO achieved durable responses as salvage/bridging therapy in patients with R/R B-ALL, enabling 96% of patients to proceed to CAR-T therapy with acceptable toxicity profile. CAR-T: chimeric antigen receptor T-cell, CD: cluster of differentiation, CRS: cytokine release syndrome; CVD: cyclophosphamide, vincristine, dexamethasone; IEC-HS: immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome; ICANS: immune effector cell-associated neurotoxicity syndrome; InO: inotuzumab ozogamicin; MRD: measurable residual disease; OS: overall..."
CAR T-Cell Therapy • Clinical • IO biomarker • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology • CD22
|
|
Anupa John DM 1; Alok Shetty DM 1; Lingaraj Nayak DM 1; Bhausaheb Bagal DM 1; BS Girish PharmD 1; CS Meghana PharmD 1; Yuktam Yadav BPharm 2; Smrithi Ravikumar MSc 2; Devanshi Kalra MSc 2; LK Aishwarya PharmD 2; Atharva Karulkar PhD 2; Rahul Purwar PhD 2; Neha Sharma MSc 1; Thomas Eipe PharmD 1; Yash Shah DM 1; Hasmukh Jain DM 1; Manju Sengar DM 1
|